These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 39115879)

  • 21. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
    Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
    Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
    [No Abstract]   [Full Text] [Related]  

  • 22. Identification of the CD8 + T-cell Related Signature for Predicting the Prognosis of Gastric Cancer Based on Integrated Analysis of Bulk and Single-cell RNA Sequencing Data.
    Zhu ZG; Wang Z; Wu Q; Miao DL; Jin YQ; Chen L
    J Immunother; 2024 Sep; 47(7):239-248. PubMed ID: 38809517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A CLRN3-Based CD8
    Gong Z; Huang X; Cao Q; Wu Y; Zhang Q
    Biomolecules; 2024 Jul; 14(8):. PubMed ID: 39199281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Construction of an immune gene expression meta signature to assess the prognostic risk of colorectal cancer patients.
    Orozco-Castaño C; Mejia-Garcia A; Zambrano Y; Combita AL; Parra-Medina R; Bonilla DA; González A; Odriozola A
    Adv Genet; 2024; 112():207-254. PubMed ID: 39396837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
    Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
    Front Immunol; 2022; 13():951455. PubMed ID: 36189298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploration of an Prognostic Signature Related to Endoplasmic Reticulum Stress in Colorectal Adenocarcinoma and Their Response Targeting Immunotherapy.
    Xu Y; Xie YM; Sun WS; Zi R; Lu HQ; Xiao L; Gong KM; Guo SK
    Technol Cancer Res Treat; 2023; 22():15330338231212073. PubMed ID: 37920989
    [No Abstract]   [Full Text] [Related]  

  • 27. Comprehensive Analysis of N6-Methyladenosine-Related lncRNA Signature for Predicting Prognosis and Immune Cell Infiltration in Patients with Colorectal Cancer.
    Zhao Z; Yang YB; Li XY; Li XG; Chu XD; Lin ZB; Zhang YR; Guo YG; Ding H; Pan YL; Wang L; Pan JH
    Dis Markers; 2021; 2021():8686307. PubMed ID: 34745388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel signature constructed by cuproptosis-related RNA methylation regulators suggesting downregulation of YTHDC2 may induce cuproptosis resistance in colorectal cancer.
    Zhao Z; Miao Z; Hou Y; Zhong Y; Zhang X; Fang X
    Int Immunopharmacol; 2024 Sep; 139():112691. PubMed ID: 39029230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
    Wang L; Zhang S; Li H; Xu Y; Wu Q; Shen J; Li T; Xu Y
    BMC Cancer; 2021 Jul; 21(1):876. PubMed ID: 34332578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel prognostic immunoscore based on The Cancer Genome Atlas to predict overall survival in colorectal cancer patients.
    Tang Z; Wu Y; Sun D; Xue X; Qin L
    Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34608935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developing a machine learning-based prognosis and immunotherapeutic response signature in colorectal cancer: insights from ferroptosis, fatty acid dynamics, and the tumor microenvironment.
    Zhu J; Zhang J; Lou Y; Zheng Y; Zheng X; Cen W; Ye L; Zhang Q
    Front Immunol; 2024; 15():1416443. PubMed ID: 39076986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.
    Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J
    Front Immunol; 2021; 12():788431. PubMed ID: 34970268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. To explore the prognostic characteristics of colon cancer based on tertiary lymphoid structure-related genes and reveal the characteristics of tumor microenvironment and drug prediction.
    Wang Z; Niu D
    Sci Rep; 2024 Jun; 14(1):13555. PubMed ID: 38867070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishment of a novel prognostic signature based on an identified expression profile of integrin superfamily to predict overall survival of patients with colorectal adenocarcinoma.
    Yu J; Yang K; Zheng J; Sun X; Zhao W
    Gene; 2022 Jan; 808():145990. PubMed ID: 34624456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DEPDC1B: A novel tumor suppressor gene associated with immune infiltration in colon adenocarcinoma.
    Zhu D; Feng H; Zhang Z; Li J; Li Y; Hou T
    Cancer Med; 2024 Aug; 13(15):e70043. PubMed ID: 39087856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive analysis of prognostic immune-related genes in the tumor microenvironment of colorectal cancer.
    Li W; Jin X; Guo S; Xu F; Su X; Jiang X; Wang G
    Aging (Albany NY); 2021 Feb; 13(4):5506-5524. PubMed ID: 33536348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel hypoxia- and lactate metabolism-related molecular subtyping and prognostic signature for colorectal cancer.
    Huang A; Sun Z; Hong H; Yang Y; Chen J; Gao Z; Gu J
    J Transl Med; 2024 Jun; 22(1):587. PubMed ID: 38902737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
    Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
    Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.
    Wang L; Yao Y; Xu C; Wang X; Wu D; Hong Z
    Technol Cancer Res Treat; 2021; 20():15330338211052154. PubMed ID: 34806485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.